VAERS Explorer
Back to explore

Report #2883306

Received Jan 28, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Unknown
Age
Age unknown
State
—
Recovered
Unknown
Vaccinated
—
Onset
—
Days to onset
—
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
COVID19COVID19 (COVID19 (PFIZER-BIONTECH))PFIZER\BIONTECH1——

Symptoms (1)

Arthritis

Symptom narrative

Severe arthritis in my hands; This is a spontaneous report received from an Other HCP and a Consumer or other non HCP, Program ID. A patient (age and gender not provided) received BNT162b2 omicron (lp.8.1) (COMIRNATY (2025-2026 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary immunization series complete, manufacturer unknown), for COVID-19 immunization. The following information was reported: ARTHRITIS (non-serious), outcome "unknown", described as "Severe arthritis in my hands". The patient reported he/she developed severe arthritis in hands after the last Covid booster. The information on the batch/lot number for BNT162b2 omicron (lp.8.1) will be requested and submitted if and when received. Amendment: This follow-up report is being submitted to amend previously reported information: remove benefit-risk comment. Amendment: This follow-up report is being submitted to amend previously reported information: to update the report type to spontaneous.; Sender's Comments: Based on the information currently available, there is not enough evidence to attribute the event "hand arthritis" to the suspect drug. Relevant information including patient's demographics, clinical course, relevant medical history and concomitant medication was not provided. This case will be re-evaluated upon receipt of additional information.